 LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 GLOBE NEWSWIRE -- Mereo BioPharma Group plc NASDAQ: MREO Mereo or the Company, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the closing of its previously announced underwritten public offering of 39,675,000 American Depositary Shares ADSs, at a public offering price of 2.90 per ADS, which includes 5,175,000 additional ADSs issued upon the exercise in full of the underwriters option to purchase additional ADSs. Each ADS represents five ordinary shares of Mereo. The aggregate gross proceeds to Mereo from the offering, before deducting underwriting discounts and commissions and offering expenses were 115.1 million. All of the ADSs in the offering were sold by Mereo. 